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Edited by Jesus AvilaAbstract Nuclear aggregates of enhanced green ﬂuorescent
protein and nuclear localization signal-fused truncated N-termi-
nal huntingtin containing 150 repeats of glutamine residue were
puriﬁed from ecdysine-inducible mutant neuro2A cell line by
sequential extraction of nuclear soluble proteins. To analyze the
aggregate-interacting proteins, we subjected the nuclear aggre-
gates to high performance liquid chromatography–mass spec-
trometry analysis. The resulting data revealed the presence of
three new putative aggregate-interacting proteins: ubiquilin 1,
ubiquilin 2 and Tollip. These proteins also associated with
neuronal intranuclear inclusions in a mouse model of Huntington
disease (HD). These aggregate-interacting proteins contain
ubiquitin-interacting motifs, suggesting that they are recruited
to the aggregates where they may lose their normal function.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Huntington disease (HD) is a hereditary neurodegenerative
disease caused by an expansion of the CAG repeat located in
exon 1 of the HD gene [1]. Expansion of the polyglutamine
(polyQ) stretch in huntingtin (htt), the HD gene product, leads
to the formation of intracellular aggregates [2,3]. Some recent
studies demonstrate that nuclear accumulation of insoluble
polyQ aggregates or formation of neuronal intranuclear in-
clusions closely correlate with disease progression [4–6], how-
ever it is still unclear whether these aggregates represent a step
in pathogenesis or even a protective mechanism.
There are many aggregate-interacting proteins (AIPs), some
of which, including the heat shock protein (Hsp) 40, 70 and 90
families, are thought to suppress aggregate formation and
cellular toxicity induced by expanded polyQ proteins [7,8]. In* Corresponding author. Fax: +81-48-4624-796.
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Abbreviations: PolyQ, polyglutamine; HD, Huntington disease; htt,
huntingtin; AIP, aggregate-interacting protein; EGFP, enhanced green
ﬂuorescent protein; MS, mass spectrometry; UBA, ubiquitin-associ-
ated; Tollip, Toll interacting protein; CUE, coupling of ubiquitin
conjugation to endoplasmic reticulum degradation; UIM, ubiquitin-
interacting motif; UBL, ubiquitin-like
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scription factors [9–11] and members of ubiquitin/proteosome
pathway [12,13], are sequestrated in the polyQ aggregates,
which could cause their loss of function and result in cellular
dysfunction. These studies suggest that the components of
AIPs reﬂect either the cellular defense against polyQ aggre-
gates or the cellular machinery aﬀected by polyQ aggregates.
Therefore, identiﬁcation of AIPs should help elucidate the
process of aggregate formation, the cellular response to ag-
gregates, and the mechanisms of cellular dysfunction caused by
the aggregates. Indeed, we have shown that components
of cytoplasmic polyQ aggregates can suppress aggregate
formation [8].
In this report, we identiﬁed components of nuclear polyQ
AIPs from Neuro2a cells stably transfected with tNhtt-150Q-
EGFP-NLS, a cDNA encoding htt exon 1 containing 150
CAG repeats and fused with enhanced green ﬂuorescent pro-
tein (EGFP) and nuclear translocation signals. Expression of
the protein by ecdysone induction caused the formation of
nuclear polyQ aggregates [14]. Using this cell model, we have
established a method for isolating nuclear polyQ aggregates,
which we analyzed by mass spectrometry (MS). These studies
identiﬁed new AIPs, including ubiquilin 1 and ubiquilin 2,
which contain the ubiquitin-associated (UBA) domain, and
Toll interacting protein (Tollip), which contains the coupling
of ubiquitin conjugation to endoplasimic reticulum degrada-
tion (CUE) domain. We also show that these ubiquitin-inter-
acting proteins are associated with neuronal intranuclear
inclusions in a mouse model of HD.2. Materials and methods
2.1. Mice
Heterozygous htt exon 1 transgenic male mice of the R6/2 (145 CAG
repeats) strain [Jackson code, B6CBA-TgN (HD exon 1) 62] were
obtained from Jackson Laboratory (Bar Harbor, ME). R6/2 mice and
their age-matched controls at 15 weeks of age were killed and their
brains were collected. Mouse experiments were approved by the animal
experiment committee of the RIKEN Brain Science Institute.
2.2. Cell culture
Neuro2a cell lines stably transfected with and expressing tNhtt-
150Q-EGFP (HD150Q cells) or tNhtt-150Q-EGFP-NLS (HD150Q-
NLS cells) were previously established using the ecdysone-inducible
mammalian expression system (Invitrogen, Carlsbad, CA) [14,15].
These cells were maintained in Dulbecco’s modiﬁed Eagle’s mediumblished by Elsevier B.V. All rights reserved.
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bovine serum and penicillin-streptomycin (Invitrogen) at 37 C in an
atmosphere containing 5% CO2. To diﬀerentiate the cells, 5 mM N6,20-
O-dibutyryl cyclic AMP (dbcAMP; Nacalai Tesque, Kyoto, Japan)
was added and to induce the expression of the tNhtt-polyQ-EGFP or
tNhtt-polyQ-EGFP-NLS proteins, 1 lM ponasterone A (Invitrogen)
was added to the medium.
2.3. Plasmids and transfection
The cDNAs for mouse Tollip and ubiquilin 1 were obtained by re-
verse transcriptase-PCR from the total RNA fraction of HD150Q-
NLS cells. The cDNAs for mouse ubiquilin 2 were obtained from the
total RNA fraction of adult mouse brain. PCR products were ampli-
ﬁed from the cDNAs and were subcloned into the TOPO-pcDNA3.1/
V5-His mammalian expression vector (Invitrogen). All constructs were
veriﬁed by DNA sequencing. Each plasmid was transfected into the
cells using LipofectAMINE 2000 (Invitrogen).
2.4. Antibodies
Polyclonal antibodies were generated in rabbits. Anti-ubiquilin 2
antibody, Ab-Ubql-2, was generated against a peptide corresponding
to amino acids 2–18 of mouse ubiquilin 2, and the anti-Tollip an-
tibodies, Ab-Tollip-M and Ab-Tollip-C, were generated against
peptides corresponding to amino acids 148–163 and 256–274 of
mouse Tollip, respectively. An N- or C-terminal cysteine residue was
added to each peptide for coupling to keyhole limpet hemocyanin or
to SulfoLink Coupling Gel (Pierce Biotechnology, Rockford, IL).
These polyclonal antibodies were aﬃnity puriﬁed using the SulfoLink
kit (Pierce Biotechnology). Monoclonal anti-htt (MAB5374) and
monoclonal anti-ubiquitin (MAB1510) were from Chemicon Inter-
national (Temecula, CA); monoclonal anti-Hdj-2 (MS-225) was from
Neomarkers (Union City, CA); monoclonal anti-GFP (clones 7.1
and 13.1) was from Roche Molecular Biochemicals (Indianapolis,
IN); rabbit polyclonal anti-ubiquilin (#662052) was from Calbio-
chem (La Jolla, CA); rabbit polyclonal anti-ubiquitin (Z0458) was
from Dako (Glostrup, Denmark); rabbit polyclonal anti-Hdj-1 (SPA-
400) was from StressGen Biotechnologies (Victoria, BC, Canada);
monoclonal anti-V5 (R960-25) and horseradish peroxidase (HRP)-
conjugated anti-V5 (R961-25) were from Invitrogen; and goat
polyclonal anti-Hsc 70 (SC-1059) and goat polyclonal anti-lamin B
(SC-6217) were from Santa Cruz Biotechnology (Santa Cruz, CA).
HRP-conjugated anti-mouse IgG (NA931V) and anti-rabbit IgG
(NA934V) were from Amersham Biosciences (Buckinghamshire,
UK); and HRP-conjugated anti-goat IgG (#705-035-147) was from
Jackson ImmunoResearch Laboratories (West Grove, PA). Anti-
mouse IgG conjugated with Alexa-546 (A-11030) and anti-rabbit IgG
conjugated with Alexa-488 (A-11008) were from Molecular Probes
(Eugene, OR).
2.5. Immunocytochemistry and immunohistochemistry
HD150Q-NLS cells growing in 4-well chamber slides were trans-
fected with 0.25 lg of TOPO-pcDNA3.1/V5-His vector containing
LacZ, ubiquilin 1, ubiquilin 2 or Tollip. One day after transfection,
cells were diﬀerentiated and induced to express tNhtt-150Q-EGFP-
NLS. After 3 days, the cells were washed twice with cold phosphate
buﬀered saline (PBS), ﬁxed for 20 min in PBS containing 4% para-
formaldehyde, washed twice with PBS, permeabilized for 5 min with
PBS containing 0.5% Triton X-100, washed several times with PBS,
blocked for 1 h with 0.05% Tween 20/Tris-buﬀered saline (TBST)
containing 2% non-fat dried milk, and incubated overnight at 4 C
with primary antibodies (1:1000 for anti-V5 and 1:500 for anti-lamin
B). Next, the cells were washed three times with TBST, incubated at
room temperature for 1 h with 1:500 Alexa-546 conjugated secondary
antibody, and washed three times with TBST. The frozen brains of R6/
2 mice mounted in Tissue-Tek were cut into 10 lm sections with a
freezing microtome. The sections were washed twice with PBS, ﬁxed
for 30 min with 100% methanol, washed several times with PBS,
blocked for 1 h with TBST containing 2% non-fat dried milk, and then
incubated overnight at 4 C with primary antibodies. The sections were
washed three times with TBST and incubated for 1 h with 1:500 Alexa-
488 conjugated secondary antibodies, washed three times with TBST,
incubated for 2 h with monoclonal 1:1000 anti-ubiquitin or mono-
clonal 1:500 anti-htt antibody, washed three times with TBST, incu-
bated for 1 h with 1:500 Alexa-546 conjugated secondary antibody,
and washed three times with TBST.2.6. Isolation of nuclear polyQ aggregates
HD150Q-NLS cells were plated in 150-mm dishes and cultured
overnight. The medium was supplemented with 5 mM dbcAMP or
both with 5 mM dbcAMP and 1 lM ponasterone A. After 3 days, the
cells were washed twice with ice-cold PBS and collected by centrifu-
gation at 1000 rpm for 5 min. Nuclei of these cells were isolated as
described previously [16,17] with a slight modiﬁcation. 1 108
HD150Q-NLS cells treated with 5 mM dbcAMP (HD150Q-NLS-D
cells) or both 5 mM dbcAMP and 1 lM ponasterone A (HD150Q-
NLS-D/I cells) were resuspended in 5 ml of 10 mM Tris–HCl, pH 7.4,
containing 2 mM MgCl2, 1% NP-40, 2 mM dithiothreitol (DTT), 1
mM phenylmethylsulfonyl ﬂuoride (PMSF) and Complete protease
inhibitor EDTA-free (Roche Molecular Biochemicals). After 5 min on
ice, the same volume of deionized distilled water was added and
swelling on ice was performed for an additional 5 min. Cells were
sheared by ﬁve passages through a 22-gauge needle and nuclei were
recovered by centrifugation at 300 g for 6 min at 4 C. Collected
nuclei were resuspended in Buﬀer A (10 mM Tris–HCl, pH 7.4, 5 mM
MgCl2, 0.25 M sucrose, 2 mM DTT, 1 mM PMSF, and Complete
protease inhibitor EDTA-free) containing 1% NP-40, 500 U/ml DNase
I (Sigma, Steinheim, Germany) and 15 U/ml RNase A (Nacalai Tes-
que), mixed for 60 min at 37 C, and centrifuged at 1500 g for 5 min.
The pellets were resuspended in Buﬀer A containing 2 M NaCl, mixed
for 60 min at 4 C, and centrifuged at 1500 g for 5 min. The pellets
were resuspended in Buﬀer A containing 4% sarcosyl (Nacalai Tesque),
mixed for 60 min at 4 C, and centrifuged for 30 min at 186 000 g.
The pellets were further washed with Buﬀer A containing 4% sarcosyl,
centrifuged for 30 min at 186 000 g, and collected as the ﬁnal nuclear
insoluble fraction.2.7. Isolation of cytoplasmic polyQ aggregates
EGFP-positive cytoplasmic polyQ aggregates were collected using a
ﬂuorescence-activated cell sorter (FACS; Epics Elite ESP, Beckman
Coulter, Fullerton, CA) as described previously [8]. Brieﬂy, HD150Q
cells were plated in a 150-mm dish and cultured overnight. The me-
dium was supplemented with 5 mM dbcAMP and 1 lM ponasterone A
(HD150Q-D/I cells). After two days, the cells were washed twice with
PBS and resuspended in PBS containing 10 mM MgCl2, 500 U/ml
DNase I, and 1 U/ml RNase A. The cells were homogenized on ice by
30 strokes at 3000 rpm in a Potter-Elvehjem-type homogenizer with a
Teﬂon pestle controlled by a Digital Homogenizer (As One, Osaka,
Japan). The homogenate was applied directly to the argon laser-loaded
FACS. The conditions for FACS were as described previously [8].
The collected aggregates were washed twice with PBS containing 4%
sarcosyl.
2.8. Identiﬁcation of AIPs by MS
Puriﬁed cytoplasmic aggregates from HD150Q-D/I cells and the ﬁ-
nal nuclear insoluble fraction of HD150Q-NLS-D and HD150Q-NLS-
D/I cells were boiled in sample buﬀer for SDS–PAGE for 5 min and
electrophoresed in a 10% polyacrylamide gel. The gels were stained
with SYPRO Ruby (Molecular Probes) and bands in the gels were
detected on a UV transilluminator. Each visible band in the insoluble
fraction of HD150Q-NLS-D/I cells was excised. For the insoluble
fraction of HD150Q-NLS-D cells, gel regions were excised at the same
molecular weights as the visible bands in the HD150Q-NLS-D/I in-
soluble fraction. In-gel digestion was carried out as described elsewhere
[18] with a slight modiﬁcation. The excised gel piece was washed sev-
eral times for 10 min at 37 C with 500 ll deionized distilled water.
SYPRO Ruby was removed from the gel piece by incubation for 10
min at 37 C in 100 ll of 50 mM NH4HCO3, pH 8.5/50%, CH3CN.
The destained gel piece was dehydrated in 50 ll of CH3CN for 10 min
at 37 C. The gel piece was reduced by adding 50 ll of 0.01 M DTT/100
mMNH4HCO3 and incubating for 15 min at 50 C, and then alkylated
by adding 2 ll of 0.25 M iodoacetate/100 mM NH4HCO3 and incu-
bating for 15 min at room temperature. After washing once with 50 ll
of 100 mM NH4HCO3 and once with 50 ll of 50 mM NH4HCO3/50%
CH3CN, the gel piece was dried by vacuum centrifugation. The dried
gel piece was covered with 12.5 ng/ll trypsin/100 mM NH4HCO3 and
then incubated overnight at 37 C. The tryptic peptides were extracted
from the gel by successive incubations with: (i) 50 ll of 50% CH3CN/
1% triﬂuoroacetic acid for 10 min at 37 C, (ii) 50 ll of 20% HCOOH/
25% CH3CN/15% isopropanol/40% H2O for 15 min at 37 C, and (iii)
50 ll of 80% CH3CN for 2 min at 37 C. The extracts from each step
were combined and dried by vacuum centrifugation. For peptide
Fig. 1. Puriﬁcation of nuclear polyQ aggregates. (A) Samples of
isolated nuclei and the ﬁnal insoluble fraction of HD150Q-NLS-D/I
cells were processed for immunocytochemistry. The pictures show
merged images of EGFP ﬂuorescence, anti-lamin B staining (Alexa-
546 as the secondary antibody, red) and chromosome staining with 40,
60-diamidino-2-phenylindole, dihydrochloride (DAPI, blue). Bar¼ 10
lm. (B) SDS–PAGE of puriﬁed cytoplasmic aggregates (2.5 106)
from HD150Q-D/I cells (left lane), nuclear insoluble fraction which
contains 5 106 nuclear aggregates of HD150Q-NLS-D/I cells (right
lane), and the nuclear insoluble fraction of HD150Q-NLS-D from the
same amount of nuclei used for the HD150Q-NLS-D/I nuclear in-
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nano electrospray ionization source (Thermo Electron Corp., Wal-
tham, MA) combined with a reverse-phase capillary column (Cadenza
C18, 0.2 50 mm, Microme BioResources, Inc., Auburn, CA) on a
Magic 2002 high performance liquid chromatography system (Mi-
crome BioResources, Inc.). The dried tryptic peptides were suspended
in 40 ll of 0.1% triﬂuoroacetic acid, of which 10 ll was applied to the
liquid chromatography/MS system. The peptide mixture was separated
using mobile phases A and B with a linear gradient over 35 min of 5–
65% B, followed by a quick shift to 5% B in 1 min and maintenance at
5% B for 4 min at a ﬂow rate of 1 ll/min (mobile phase A ¼ 2%
CH3CN/0.1% HCOOH and mobile phase B ¼ 90% CH3CN/0.1%
HCOOH). The separated peptide fragments were sprayed from a 15
lm i.d. (inner diameter) Picotip (New Objectives, Woburn, MA) and
ionized under 1.8 kV of ion spray voltage with a capillary temperature
of 260 C. The scanned mass range was 400–2000 m/z and the dynamic
exclusion mode was activated throughout the scan. The minimum in-
tensity MS peak for tandem MS (MS/MS) analysis was 2.5 105
counts. The MS spectra and MS/MS spectra data were collected by
Xcalibur software (Matrix Science, London, UK). The data were an-
alyzed for predicting candidate sequence for the AIPs with MASCOT
software (Matrix Science) using the public domain protein database
(National Center for Biotechnology Information).
2.9. Western blots
Cell lysates, nuclear fractions, and puriﬁed aggregates were pre-
pared as described in Sections 2.5 and 2.6. These materials (20 lg/lane
cell lysate, 1 106 nuclear aggregate particles/lane, or 0.5 106 cy-
toplasmic aggregate particles/lane) were subjected to SDS–PAGE and
then electrophoretically transferred to a polyvinylidene ﬂuoride
membrane. After blocking the membrane with TBST containing 2%
non-fat milk, the membrane was incubated overnight at 4 C with
primary antibodies (1:2000 for anti-GFP and anti-V5-HRP; 1:1000
for anti-Hdj-1, anti-Hdj-2 and anti-Hsc 70; and 1:500 for anti-htt and
anti-ubiquilin) in TBST, washed three times with TBST, incubated for
1 h at room temperature with 1:2000 HRP-conjugated secondary
antibodies in TBST, and washed three times. Immunoreactive pro-
teins were detected with enhanced chemiluminescence reagents
(Amersham Biosciences).soluble fraction (middle lane). (C) Western blotting for GFP (for
tNhtt-150Q-EGFP-NLS), ubiquitin (Ub), Hsc 70, Hdj-1 and Hdj-2 in
the insoluble fraction of HD150Q-NLS-D or HD150Q-NLS-D/I cells.
Arrow heads indicate gel excluded materials immunoreactive with
each antibodies. Arrows indicate each antigenic protein. Ubiquitin
immunoreactivity was observed in the gel top and diﬀuse smearing.
Wh, whole cell lysate; Nuc, nuclear fraction; Nuc-Ins, ﬁnal insoluble
fraction of the nuclei.3. Results
3.1. Puriﬁcation of tNhtt-150Q-EGFP-NLS and
tNhtt-150Q-EGFP aggregates
To purify the nuclear polyQ aggregates, we isolated the
nuclei of the HD150Q-NLS-D (diﬀerentiated) and HD150Q-
NLS-D/I (diﬀerentiated/induced) cells and performed sequen-
tial extractions of soluble nuclear proteins. DNA-associated
proteins and DNA can be removed from the nuclei by treat-
ment with DNase I [19], while nuclear matrix components can
be removed by incubation with RNase A, followed by 2 M
NaCl [20]. Therefore, to isolate insoluble nuclear components,
we treated the isolated nuclei with a combination of RNase
and DNase, followed by 2 M NaCl. We also removed re-
maining soluble nuclear proteins from the nuclei with 4%
sarcosyl. As shown in Fig. 1A, the nuclear lamina and chro-
mosomal structures were disrupted, and variable sizes of
EGFP-positive nuclear aggregates were found in the ﬁnal nu-
clear insoluble fraction. SDS–PAGE of the nuclear insoluble
fraction of HD150Q-NLS-D/I cells showed many bands
(Fig. 1B, right lane), while that of HD150Q-NLS-D cells
lacked distinct bands (Fig. 1B middle lane). Thus, most of the
nuclear proteins were removed from the nuclei by the se-
quential treatments of DNase/RNase, NaCl, and sarcosyl.
To conﬁrm the existence of tNhtt-150Q-EGFP-NLS and
other proteins previously reported as AIPs in nuclear insoluble
fraction, we conducted Western blot analysis of whole cell
lysates, nuclear fractions, and nuclear insoluble fractions(Fig. 1C) from HD150Q-NLS-D and D/I cells. Western blot-
ting with an anti-GFP antibody detected an 80-kDa band in
the nuclear insoluble fraction of HD150Q-NLS-D/I cells,
corresponding to the tNhtt-150Q-EGFP-NLS protein. This
antibody also detected concentrated aggregates at the top of
the gel in the nuclear insoluble fraction from HD150Q-NLS-
D/I cells. Ubiquitin, Hsc 70, Hdj-1 and Hdj-2 were detected in
the nuclear insoluble fraction from HD150Q-NLS-D/I cells.
3.2. Identiﬁcation of UBA and CUE domain containing proteins
in the puriﬁed nuclear polyQ aggregates
Following SDS–PAGE of the puriﬁed nuclear polyQ ag-
gregates from HD150Q-NLS-D/I cells, each band was excised,
digested with trypsin, and subjected to MS/MS analysis. As a
negative control, we also excised and analyzed the gel pieces in
the SDS–PAGE of the nuclear insoluble fraction from
HD150Q-NLS-D cells. We identiﬁed several proteins con-
taining UBA or CUE domains (Table 1) in the puriﬁed nuclear
polyQ aggregates from the HD150Q-NLS-D/I cells. We also
found members of the Hsp 70 and 40 families. These proteins
were not found in the insoluble fraction of HD150Q-NLS-D
cells.
Table 1
AIP candidates suggested by MS/MS analysis
Identiﬁed proteins Nominal massa (Da) Sequence coverageb (%) GI numberc Accession number
Ubiquilin 1 61 976 12 20072434 BC026847.1
Ubiquilin 2 67 379 16 34328236 NM_018798.2
Tollip 30 573 21 13591860 NM_023764.2
Hsc 70 71 021 34 476850 A45935
Hsp 40 45 581 73 6680297 NM_008298.2
aMolecular weight of each protein as calculated by MASCOT.
b Percentage of amino acids in the full-length protein covered by the identiﬁed peptides.
c ‘‘GenInfo Identiﬁer’’ sequence identiﬁcation number for the protein.
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aggregates in the nuclei of HD150Q-NLS cells
We next used immunocytochemistry to determine whether
these UBA and CUE domain-containing proteins co-localize
with polyQ aggregates. The cDNA of mouse ubiquilin 1,
ubiquilin 2 and Tollip were cloned into the TOPO-pcDNA3.1/
V5-His mammalian expression vector, after which the con-
structs were transfected into HD150Q-NLS cells. Fig. 2 shows
that the V5-tagged AIP candidates co-localized with nuclear
polyQ aggregates. Although overexpressed ubiquilin 1, ubiq-
uilin 2 and Tollip accumulated in the perinuclear regions of the
cells (data not shown), we conﬁrmed that ubiquilin 1, ubiquilin
2 and Tollip co-localized with nuclear polyQ aggregates in
some cells (co-localization ratio¼ the number of cells having
V5-positive aggregates/the number of transfected cells having
aggregates: LacZ, 0%; ubiquilin 1, 13%; ubiquilin 2, 18%;
Tollip, 35% in HD150Q-NLS-D/I cells and; LacZ, 3.7%;Fig. 2. Ubiquitin-interacting proteins are associated with polyQ ag-
gregates. Immunocytochemistry of HD150Q-NLS cells transfected
with Lac Z-V5-His, ubiquilin 1-V5-His, ubiquilin 2-V5-His and Tollip-
V5-His. Each overexpressed protein is labeled by anti-V5 antibody
(Alexa ﬂuor 546 as the secondary antibody, red). Ubiquilin 1-V5-His,
ubiquilin 2-V5-His and Tollip-V5-His co-localized with nuclear polyQ
aggregates of the HD150Q-NLS cells. Bar¼ 10 lm.ubiquilin 1, 61%; ubiquilin 2, 79%; Tollip, 83% in HD150Q-D/
I cells.)
3.4. Ubiquitin-interacting proteins exist in puriﬁed cytoplasmic
and nuclear polyQ aggregates
We performed Western blotting to verify the presence of
these proteins in the aggregates. To this end, we generated
polyclonal antibodies Ab-Ubql-2 against ubiquilin 2 and Ab-
Tollip-M and Ab-Tollip-C against Tollip (Fig. 3A). We also
used a commercially available rabbit polyclonal anti-ubiquilinFig. 3. Ubiquitin-interacting proteins exist in puriﬁed cytoplasmic and
nuclear aggregates. (A) Characterization of anti-ubiquilin (Ab-Ubql-
1), Ab-Ubql-2, Ab-Tollip-M, and Ab-Tollip-C antibodies. Ab-Ubql-1
recognizes endogenous and overexpressed ubiqulin 1 and an 80 kDa
non-speciﬁc band. Ab-Ubql-2 recognizes endogenous and overex-
pressed ubiquilin 2 and its 90 kDa derivative. Ab-Tollip-M and -C
recognize endogenous and overexpressed Tollip. Ab-Tollip-M also
detects its derivatives. Cell lysates from HD150Q-NLS cells transfected
with; N-lane, no vector; 1-lane, ubiquilin 1-V5-His expressing vector;
2-lane, ubiquilin 2-V5-His expressing vector; or T-lane, Tollip-V5-His
expressing vector. Arrows indicate endogenous protein and arrow
heads indicate overexpressed protein. (B) Ubiquilins 1, ubiquilin 2 and
Tollip coexist in puriﬁed cytoplasmic and nuclear poly Q aggregates.
C-lane, puriﬁed cytoplasmic aggregates of HD150Q-D/I cells; D-lane,
nuclear insoluble fraction of HD150Q-NLS-D cells; D/I-lane, puriﬁed
nuclear aggregates of HD150Q-NLS-D/I cells.
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tern blot analysis conﬁrmed that ubiquilin 1, ubiquilin 2 and
Tollip co-purify with nuclear polyQ aggregates (Fig. 3B).
These proteins were also recognized in puriﬁed cytoplasmic
aggregates fraction (Fig. 3B). These ﬁndings suggested that
ubiquilin 1, ubiquilin 2 and Tollip are strongly associated with
polyQ aggregates and shift to the insoluble fraction upon
formation of polyQ aggregates.
We also used anti-GFP immunoprecipitation to determine
whether the ubiquitin-interacting proteins associate with sol-
uble tNhtt-150Q-EGFP-NLS in the HD150Q-NLS cells. We
found that Hdj-2 but not soluble Tollip or ubiquilin 1 and 2
co-immunoprecipitate with tNhtt-150Q-EGFP-NLS (data not
shown). Thus, Tollip and ubiquilin 1 and 2 interact speciﬁcally
with the insoluble and highly ubiquitinated form of tNhtt-
150Q-EGFP-NLS.
3.5. Tollip and ubiquilin 1 and 2 co-localize with neuronal
nuclear inclusions in a transgenic mouse model of HD
Our results suggested that ubiquilin 1, ubiquilin 2 and Tollip
are AIPs. To investigate this further, we examined whether
these proteins associate with polyQ aggregates in HD exon 1
transgenic mice (R6/2 mice) [21]. Immunostaining of R6/2
transgenic mouse brain sections showed that ubiquilin 1,
ubiquilin 2 and Tollip co-localize with ubiquitin and htt im-
munoreactive neuronal intranuclear inclusions, while immu-
nostaining of age-matched control mouse brain sections
showed that ubiquilin 1, ubiquilin 2 and Tollip did not form
intranuclear inclusions (Fig. 4). We also counted two hundred
htt-positive neuronal intranuclear inclusions both in the cortex
and striatum of R6/2 transgenic mouse. We conﬁrmed that all
of the inclusions associated with ubiquilin 1, ubiquilin 2 or
Tollip. These ﬁndings indicate that our method for purifying
nuclear polyQ aggregates from a cell-based model can identify
AIPs associated with a mouse model of HD.Fig. 4. Ubiquitin-binding proteins are associated with neuronal intranuclea
transgenic and wild type mice were double-labeled with a monoclonal anti-u
Ubql-1, Ab-Ubql-2, or Ab-Tollip-M antibodies (Alexa-488, green), followed
cerebral cortex stained with each AIP antibody, anti-htt and DAPI was sh
intranuclear inclusions of transgenic mouse. Bar¼ 20 lm.4. Discussion
In this study, we established a method for purifying nuclear
polyQ aggregates from a cell model of HD. There have been a
few attempts to purify the polyQ aggregates and to directly
identify their components [8,22,23]. In one of these studies,
polyQ aggregates were isolated by detergent insolubility and
density gradient fractionation [22], while other studies col-
lected aggregates depending on GFP ﬂuorescence by using
FACS [8,23]. These methods successfully isolated uniform and
particle-like aggregates. In the current studies, we puriﬁed the
nuclear aggregates by sequential removal of soluble proteins.
This method was intended to identify the nuclear proteins that
are soluble under normal conditions but shift to the insoluble
upon formation of polyQ aggregates. The advantage of our
method is that a broad range of aggregate sizes can be isolated
regardless of the intensity of the GFP ﬂuorescence. These may
include aggregates in a variety of stages of formation. More-
over, using this method, we identiﬁed not only a group of
proteins that were already known as AIPs, including members
of the Hsp 40 and 70 families, but also several ubiquitin-in-
teracting domain-containing proteins as new candidate AIPs.
UBA domain, ubiquitin-interacting motif (UIM), and CUE
domain are known to bind directly to mono- and/or polyUb
chains [24,25]. PolyQ aggregates have been reported to contain
several UBA domain-containing proteins, including p62, HHR
23A, B and A1Up, as well as UIM domain-containing pro-
teins, such as proteosome subunit S5a and ataxin 3 [26–28].
These ubiquitin-interacting proteins are thought to be se-
questered in the polyQ aggregates through these domains, and
loss of function of these proteins might be the cause of neu-
rodegeneration [26]. In this study, we showed that the UBA
domain-containing proteins, ubiquilin 1 and 2, and the CUE
domain-containing protein, Tollip, are associated with polyQ
aggregates in both cellular and mouse models of HD. Theser inclusions. Frozen sections of cerebral cortex prepared from R6/2
biquitin or a monoclonal anti-htt antibody (Alexa-546, red) and Ab-
by staining with DAPI (blue). As for wild type, only merged image of
own. Ubiquilins 1, ubiquilin 2 and Tollip co-localized with neuronal
176 H. Doi et al. / FEBS Letters 571 (2004) 171–176proteins had not been previously reported to associate with
polyQ aggregates.
Ubiquilins, also known as plics, are members of the proteins,
which possess an N-terminal ubiquitin-like (UBL) domain and
a C-terminal UBA domain, and are closely related to A1Up,
which interacts with ataxin 1 [28]. The UBL domain interacts
with subunit of the 19S complex and UBA domains interact
with K48-linked polyubiquitin chains [29,30]. Overexpression
of ubiquilins interferes with ubiquitin/proteosome-dependent
degradation of p53 and IjBa [31]. In addition, disruption of
DSK2, a yeast homolog of ubiquilin, inhibits the degradation
of a model substrate, and overexpression of Dsk2 protein
causes the accumulation of polyubiquitin protein [29]. Thus,
ubiquilins are thought to modulate the ubiquitin/proteosome
pathway. Ubiquilin 1 is also known to stabilize intracellular
GABAA receptor subunits and to increase the number of re-
ceptors in the plasma membrane [32], suggesting that ubiquilin
1 has a crucial role in the neuron. Furthermore, ubiquilin 1 co-
localizes with neuroﬁbrillary tangles in Alzheimer disease and
with Lewy Bodies in Parkinson disease [33], indicating that
ubiquilin may play a role in neurodegenerative diseases.
Tollip was initially identiﬁed as a modulator of interleukin-1
signaling [34]. This protein has an N-terminal protein kinase C
conserved region 2 (C2 domain) and a C-terminal CUE do-
main. A recent study revealed that Tom 1, a VHS (Vps27, Hrs
and STAM) domain-containing protein, interacts with the N-
terminal region of Tollip, polyubiquitin chains, and clathrin
heavy chain, and that Tollip binds to polyubiquitin chains,
suggesting that the Tom 1-Tollip complex can link polyubiq-
uitinated proteins to clathrin [35]. Therefore, sequestration of
ubiquilins or Tollip in the polyQ aggregates may disrupt
normal neuronal function by altering the ubiquitin/proteo-
some pathway or clathrin-mediated vesicular traﬃcking.
A variety of methods, including yeast two-hybrid screening
[36] and genetic screening in yeast [37] or Drosophila [38], have
been utilized to identify polyQ disease-related proteins that
may mediate the neurodegenerative phenotypes. The method
employed in this report should also help identify molecules in
the polyQ disease cascade and may provide further informa-
tion on the process of polyQ aggregation and its role in neu-
rotoxicity.
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